Patents Assigned to Cour Pharmaceuticals Development Company
  • Covalent polymer-antigen conjugated particles
    Patent number: 11510996
    Abstract: The present invention provides compositions comprising tolerizing immune modified particles (TIMPs) and methods for using and making said TIMPs. In particular, carrier polymer is covalently conjugated with antigenic peptide before particle formation, which allows for exquisite control of particle size and antigen encapsulation (e.g., for use in eliciting induction of immunological tolerance).
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: November 29, 2022
    Assignees: COUR PHARMACEUTICALS DEVELOPMENT COMPANY INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Ryan Pearson, Daniel Getts, John Puisis, James Herrmann, Lonnie D. Shea
  • Process for the preparation of tolerizing immune-modulating particles
    Patent number: 11484506
    Abstract: The present disclosure is directed to a method of preparing a pharmaceutical composition comprising tolerizing immune-modulating particles of polymer-encapsulated gliadin.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: November 1, 2022
    Assignee: COUR PHARMACEUTICALS DEVELOPMENT COMPANY, INC.
    Inventors: Daniel R. Getts, Frank Fokta, Ryan Pearson
  • Modified immune-modulating particles
    Patent number: 10471093
    Abstract: The current invention involves the surprising finding that when carboxylated particles, such as carboxylated polystyrene, PLGA, or diamond particles are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same carboxylated particles.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: November 12, 2019
    Assignee: Cour Pharmaceuticals Development Company.
    Inventors: Daniel R. Getts, Rachael Terry, Nicholas King
  • Immune-modifying nanoparticles for the treatment of inflammatory diseases
    Patent number: 9919005
    Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: March 20, 2018
    Assignee: COUR PHARMACEUTICALS DEVELOPMENT COMPANY, INC.
    Inventor: Daniel R. Getts
  • Immune-modifying nanoparticles for the treatment of inflammatory diseases
    Patent number: 9913883
    Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 13, 2018
    Assignee: COUR Pharmaceuticals Development Company
    Inventor: Daniel Getts
  • IMMUNE-MODIFYING NANOPARTICLES FOR THE TREATMENT OF INFLAMMATORY DISEASES
    Publication number: 20150010631
    Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 8, 2015
    Applicant: Cour Pharmaceuticals Development Company
    Inventor: Daniel GETTS